Oregon seeks HCV Rx waiver

Share this article:

The Oregon Health Plan, which provides coverage for low-income residents, is recommending that it not cover Gilead's Sovaldi or Janssen's Olysio hepatitis C medications.

The Oregonian reports that the program wants to invoke its waiver to bar these medications for cost purposes—providing it for around 33%, or 7,000 of the plan's members, would cost $168 million a year. As a point of comparison, the plan spent a total of $377 million on medications for its 600,000 members in 2013.

The Oregonian also notes that the state is hemmed in by a 2012 agreement with the federal government which bound the state to cap expenses in exchange for $1.9 billion. Exceeding the cost limits would put the state on the hook for a penalty of hundreds of millions of dollars.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.